» Articles » PMID: 35347568

Purinergic Signaling in Thyroid Disease

Overview
Publisher Springer
Date 2022 Mar 29
PMID 35347568
Authors
Affiliations
Soon will be listed here.
Abstract

It is known that thyroid hormones play pivotal roles in a wide variety of pathological and physiological events. Thyroid diseases, mainly including hyperthyroidism, hypothyroidism, and thyroid cancer, are highly prevalent worldwide health problems and frequently associated with severe clinical manifestations. However, etiology of hyperthyroidism, hypothyroidism, and thyroid cancer is not fully understood. Purinergic signaling accounts for a complex network of receptors and extracellular enzymes responsible for the recognition and degradation of extracellular nucleotides and adenosine. It has been established that purinergic signaling modulates pathways in a wide range of physiopathological conditions including hypertension, diabetes, hepatic diseases, psychiatric and neurodegeneration, rheumatic immune diseases, and cancer. More recently, the purinergic system is found to exist in thyroid gland and play an important role in the pathophysiology of thyroid diseases. Therefore, throughout this review, we focus on elaborating the changes in purinergic receptors, extracellular enzymes, and extracellular nucleotides and adenosine in hyperthyroidism, hypothyroidism, and thyroid cancer. Profound understanding of the relationship between the purinergic signaling with thyroid diseases provides a promising research area for insights into the molecular basis of thyroid diseases and also develops new and exciting insights into the treatment of thyroid diseases, especially thyroid cancer.

Citing Articles

Causal effects of thyroid volume change on thyroid disease: a Mendelian randomization study.

Yuan H, Fang D, Wang C, Zheng K, Oh M, Wang Y Gland Surg. 2024; 13(11):2163-2173.

PMID: 39678427 PMC: 11635569. DOI: 10.21037/gs-24-441.


Identification of potential immunotherapeutic targets and prognostic biomarkers in Graves' disease using weighted gene co-expression network analysis.

Mi N, Li Z, Zhang X, Gao Y, Wang Y, Liu S Heliyon. 2024; 10(5):e27175.

PMID: 38468967 PMC: 10926144. DOI: 10.1016/j.heliyon.2024.e27175.


Editorial: Purinergic signalling - a perspective from China.

Tang Y, Chen J, Illes P Purinergic Signal. 2022; 19(1):1-3.

PMID: 36515791 PMC: 9984570. DOI: 10.1007/s11302-022-09914-x.

References
1.
Willems L, Reichelt M, Molina J, Sun C, Chunn J, Ashton K . Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts. Cardiovasc Res. 2006; 71(1):79-87. DOI: 10.1016/j.cardiores.2006.03.006. View

2.
Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss H . The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. J Nucl Med. 2020; 62(3):304-312. DOI: 10.2967/jnumed.120.243170. View

3.
Balas N, Arad M, Rabinowitz B, Shainberg A . Modulation of cardiac A1-adenosine receptors in rats following treatment with agents affecting heart rate. Mol Cell Biochem. 2002; 231(1-2):107-16. DOI: 10.1023/a:1014412814735. View

4.
Bruno A, Pochmann D, Ricachenevsky F, Fontella F, Bonan C, Dalmaz C . Nociceptive response and adenine nucleotide hydrolysis in synaptosomes isolated from spinal cord of hypothyroid rats. Neurochem Res. 2005; 30(9):1155-61. DOI: 10.1007/s11064-005-7867-3. View

5.
Desideri G, Bocale R, DAmore A, Necozione S, Boscherini M, Carnassale G . Replacement therapy with levothyroxine modulates platelet activation in recent-onset post-thyroidectomy subclinical hypothyroidism. Nutr Metab Cardiovasc Dis. 2017; 27(10):896-901. DOI: 10.1016/j.numecd.2017.07.002. View